At Sarepta, we’re committed to pursuing some of the world’s most debilitating, prevalent, and complex rare genetic diseases. Today, our primary focus is on Duchenne muscular dystrophy, limb-girdle muscular dystrophies, Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome A, and Charcot-Marie-Tooth disease.